Article Text

Download PDFPDF
Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease
  1. J van der Palen1,
  2. E Monninkhof1,
  3. P van der Valk1,
  4. S D Sullivan2,
  5. D L Veenstra2
  1. 1Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede, The Netherlands
  2. 2Department of Pharmacy, University of Washington, Seattle, USA
  1. Correspondence to:
    Dr J van der Palen
    Medisch Spectrum Twente, Concernstaf, Department of Epidemiology, P O Box 50000, 7500 KA Enschede, The Netherlands; vdpalen{at}euronet.nl

Abstract

Background: The evidence for the effectiveness and safety of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) is inconclusive. This study determined the cost effectiveness of withdrawing fluticasone propionate (FP) in outpatients with COPD.

Methods: The cost effectiveness analysis was based on a randomised, placebo controlled FP withdrawal study. After a 4 month run in period on FP, patients were randomly assigned to continue FP 500 μg twice daily or to receive placebo for 6 months. A decision analytical model evaluated the 6 month incremental cost effectiveness of the ICS versus ICS withdrawal strategy. One way sensitivity analyses and a Monte Carlo simulation were performed to evaluate the robustness of the findings.

Results: The average patient with COPD in the FP group generated €511 in direct medical costs, including €238 for FP. The cost of the placebo strategy was €456. The higher direct drug cost of €212 per patient for the FP strategy during the 6 month follow up period compared with the placebo group was partially offset by a lower exacerbation and hospital admission cost of €157. The 6 month incremental cost effectiveness of the FP strategy compared with placebo was €110 per exacerbation prevented and €1286 per hospital admission prevented.

Conclusions: Over a 6 month period, withdrawing FP in a pre-selected trial population of COPD patients led to absolute cost savings but with a higher rate of exacerbations and hospital admissions.

  • COPD, chronic obstructive pulmonary disease
  • FP, fluticasone propionate
  • ICS, inhaled corticosteroids
  • cost effectiveness
  • chronic obstructive pulmonary disease
  • steroid withdrawal

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Published Online First 21 October 2005

  • Source(s) of support in the form of grants: The Netherlands Asthma Foundation, Boehringer Ingelheim, Amicon Health Care Insurance Company, and GlaxoSmithKline BV. Source of support in the form of drugs and placebos: GlaxoSmithKline BV.

  • Competing interests: none.

  • No party had any role in the design of the study, the collecting of data, the analysis and interpretation of the data, and in the preparation, approval, and submission of the manuscript.